What’s the Average Cost of Specialty Drugs in 2026?

Specialty medications are among the fastest-growing drivers of healthcare spend in the U.S., with average monthly costs now exceeding $4,500 per therapy.[4] These treatments play a critical role in managing complex, chronic, and acute conditions—from oncology and neurology to autoimmune and rare diseases—but their pricing presents meaningful challenges across the healthcare ecosystem.

Over the past decade, specialty drug costs have risen far faster than traditional pharmaceuticals. Individual therapies can reach $6,000 per month for inflammatory conditions and exceed $20,000 for certain oncology indications.[2] Even with coverage in place, cost exposure remains a key consideration for providers, payors, manufacturers, and the patients they support.

Managing costs effectively depends on experienced specialty pharmacy and infusion partners who can align coverage strategy, care coordination, and cost optimization—without compromising clinical outcomes.

Current Specialty Drug Trends and Market Changes

The specialty drug landscape is constantly evolving as new therapies launch and biosimilars gain market share. Staying ahead of these trends enables healthcare organizations, payors, and providers to anticipate cost shifts and identify opportunities for savings.

Biosimilar Adoption Driving Savings

Biosimilars gained significant traction in 2024, with Humira® biosimilars capturing 40% of the market within a few months of launch.[3] These FDA-approved alternatives deliver equivalent clinical outcomes at lower costs. Savings multiply when organizations actively support biosimilar adoption through formulary strategies and provider education.

Key examples for ambulatory infusion and cost optimization:

• Remicade (infliximab) biosimilars: Inflectra®, Renflexis®, Avsola®
• Benefits of infusion center administration: In select scenarios, site-of-care optimization—such as administering therapies in specialized infusion centers like Continuum Health AIC, may help reduce overall treatment costs in certain cases, with savings varying based on drug, payer, and site-of-care arrangements.

Shift from Medical Benefit to Pharmacy Benefit

As more specialty medications transition to the pharmacy benefit, organizations may gain:

• Greater visibility into drug costs and utilization
• Opportunities to leverage manufacturer rebates, where available
• Potential cost savings in certain scenarios, depending on therapy and benefit structure

Specialty pharmacies support this transition by:

• Supporting prior authorizations and benefit coordination
• Ensuring accurate billing and proper reimbursement
• Overseeing complex cold-chain logistics, critical when distribution disruptions occur

Top Specialty Medications by Annual Price

Identifying the medications that drive the highest costs helps organizations focus management efforts where they matter most. High-cost therapies often target rare conditions, but even common specialty drugs carry substantial price tags.

Inflammatory Disease Treatments

Biologics for chronic inflammatory conditions such as Crohn’s disease and rheumatoid arthritis range from $70,000–$120,000 annually.[2] Some examples include:

• Entyvio (Vedolizumab)
• Stelara (Ustekinumab)

These therapies require strict temperature control and professional administration, making oversight by a specialty pharmacy essential.[5] During distribution disruptions, local networks can help ensure drug integrity and on-time delivery, while national partnerships coordinate continuity across multiple sites.

Multiple Sclerosis and Oncology Drugs

• Multiple sclerosis treatments average $95,000 per year, with medications like Ocrevus (Ocrelizumab) requiring specialized infusion services.[2]
• Oncology therapies can exceed $200,000 annually, demanding comprehensive clinical support beyond simple dispensing.[2]

Specialty infusion providers like ContinuumRx support the administration of high-cost therapies, and may help manage the overall treatment costs while maintaining appropriate clinical standards.  A controlled environment and expert oversight can help eliminate unnecessary hospital charges and support more seamless patient care.

What Drives Specialty Drug Spending for Employers?

Specialty drug spending continues to be one of the most significant cost pressures facing employers that fund health benefits for employees and their families. Today, specialty medications account for nearly 55% of total pharmacy spend while serving roughly 2% of covered members,[4] creating an outsized financial impact for benefit-sponsoring organizations.

Rising Per Member Per Year Costs

Per-member-per-year (PMPY) spending on specialty medications reached approximately $3,800 in 2024, up 7% year over year.[4]

For employers funding their own health benefits, this impact is immediate and measurable. In a workforce of 1,000 covered lives, specialty drug costs can exceed $3.8 million annually, even when utilization is limited to a small number of individuals.

Strategic site-of-care management plays a critical role in controlling these costs. Shifting high-cost infusions from hospital outpatient departments to home or ambulatory infusion settings can reduce total spend, depending on clinical appropriateness, payer policies, and contracting arrangements. These savings are driven by lower facility costs and more efficient care-delivery models, supported by specialty pharmacy partners like those affiliated with Acelpa Health.

Employer-Sponsored Health Plans

For employers that sponsor health benefits, specialty drug claims can trigger sudden, unpredictable cost spikes.

A single employee initiating therapy for multiple sclerosis, oncology, or rare disease treatment can add significantly to annual pharmacy spend. These high-cost events complicate forecasting and strain the sustainability of overall benefits.

Employers often need to turn to specialty pharmacy partners with strong clinical and infusion management capabilities to handle this challenge. Effective utilization management, coordinated care pathways, and site-of-care optimization help ensure therapies are clinically appropriate while avoiding unnecessary cost escalation. 

Specialty Pharmacy Management Strategies

Effective specialty pharmacy management balances solid patient access with cost control. Organizations benefit from strategies that address both clinical and financial complexities of high-cost therapies.

Prior Authorization and Utilization Management

Prior authorization ensures patients receive FDA-approved treatments appropriate for their conditions. When managed effectively, these programs prevent inappropriate prescribing while maintaining timely access to therapy.

Specialty pharmacies help streamline approvals by collaborating directly with providers and payors.

FDA-Approved Biosimilars 

Biosimilars offer identical efficacy at lower costs, creating significant savings opportunities. Organizations can maximize impact by:

• Implementing biosimilar-first policies for new patients
• Supporting safe transitions for stable patients
• Providing education to ensure confidence among providers and staff

High-cost therapies, including complement inhibitors such as Soliris and enzyme replacements such as Fabrazyme, require specialized handling. National specialty pharmacy networks can help ensure product integrity, optimize distribution, and deliver cost-effectively across home and ambulatory infusion settings.

Optimizing Specialty Drug Management for Better Outcomes and Cost Control

Managing specialty drug costs requires more than budgeting—it demands strategic partnerships and operational expertise. Organizations that integrate biosimilar adoption, site-of-care optimization, and full-service specialty pharmacy solutions can achieve meaningful reductions in drug spending while maintaining high-quality care.

Acelpa Health and its affiliated pharmacies provide the infrastructure, clinical expertise, and flexible delivery models to navigate these complex challenges. From home infusion to ambulatory infusion centers, we help ensure treatments are delivered safely, efficiently, and in the most cost-effective setting.

Partner with Acelpa Health to support specialty drug management and care coordination across your patient population, with a focus on cost management and adherence to clinical best practices.

Frequently Asked Questions (FAQ)

What is the average cost of a specialty drug?

Specialty drugs have an average annual cost exceeding $84,000, with some reports reaching $136,401.[6] This is more than 30 times the cost of traditional medications, which average around $2,500 per year. For health plans, spending averages approximately $38,000 per specialty patient annually.[4] Specialty infusion providers work closely with payors and leverage patient assistance programs to help manage these costs and maintain access to treatment.

What is the most expensive specialty drug?

The highest-cost specialty medications are often gene therapies and ultra-rare treatments. Examples include Zolgensma at approximately $2.125 million per dose, Myalept at $1.3 million annually, Danyelza and Zokinvy at $1.2 million annually, and Kimmtrak at $1.1 million annually.[7] These therapies require specialized handling, professional administration, and comprehensive support services, which specialty infusion providers are equipped to deliver.

What are Tier 4 specialty drugs?

Tier 4 drugs represent the highest-cost medications on insurance formularies. They typically treat complex or rare conditions such as multiple sclerosis, hepatitis C, rheumatoid arthritis, and immunodeficiencies. Specialty infusion pharmacies provide the necessary infrastructure for these medications, including cold-chain storage, trained staff for infusion administration, intensive patient monitoring, and coordination with payors to navigate coverage and prior authorization requirements.

Why are specialty drugs so expensive?

Specialty drug pricing reflects multiple factors, including complex manufacturing processes, particularly for biologics derived from living cells, high research and development costs spread across small patient populations, and limited market competition. These medications also require specialized handling, including strict temperature control, professional administration, and intensive monitoring to ensure safety and effectiveness. Manufacturers set premium pricing due to the severity, chronicity, or rarity of the conditions these drugs treat, given the limited number of alternative therapies.